evolution of the assessment of clinical benefit in polycythemia vera
Published 9 years ago • 255 plays • Length 19:36Download video MP4
Download video MP3
Similar videos
-
19:03
assessment of novel treatment options for patients with pv
-
19:02
prognostication and initiation of therapy in polycythemia vera: do we have it right?
-
13:49
“masked” polycythemia vera and polycythemia vera “in evolution”
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
25:48
the who updated diagnostic criteria for mpn
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
5:08
polycythemia vera - causes, symptoms, diagnosis, treatment, pathology
-
57:46
a conversation with an mpn specialist: polycythemia vera
-
17:52
simulating the evolution of multicellularity
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
26:50
“masked” polycythemia vera: time to change who diagnostic criteria
-
12:24
development of long-acting interferon as new therapy for pv and et
-
23:38
why mpns transform to aml
-
18:36
diagnostic challenges in mpn
-
13:09
long-acting interferon: what is the difference?
-
14:02
mpn: what is the real clinical benefit of jak2 inhibitors?
-
23:39
expert perspectives: jak inhibitors for polycythemia vera
-
21:26
the who updated diagnostic criteria for et, pv & mf